

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052121 A1

- (51) International Patent Classification⁷: **A23L 1/29**, 1/0528, 1/09
- (21) International Application Number: PCT/EP2003/014087
- (22) International Filing Date: 11 December 2003 (11.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0229015.3 12 December 2002 (12.12.2002) GB
- (74) Agents: **BOHMANN, Christine** et al.; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

- (71) Applicant (*for all designated States except US*): **NOVARTIS NUTRITION AG** [CH/CH]; Monbijoustrasse 118, CH-3001 Bern (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **GIBSON, Glenn, R.** [GB/GB]; 32 Oatlands Road, Shinfield, Reading, Berkshire RG2 9DW (GB). **BEER, Michael** [CH/CH]; Lilienweg 64, CH-3098 Köniz (CH).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PREBIOTIC COMPOSITIONS

(57) Abstract: The present invention concerns nutritional compositions comprising oligosaccharides for controlling inflammatory bowel disease and related disorders, such as diarrhoea and constipation.

WO 2004/052121 A1